Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017;8(1):7.
doi: 10.1186/s12645-017-0030-4. Epub 2017 Oct 26.

Cancer resistance to treatment and antiresistance tools offered by multimodal multifunctional nanoparticles

Affiliations
Review

Cancer resistance to treatment and antiresistance tools offered by multimodal multifunctional nanoparticles

Eudald Casals et al. Cancer Nanotechnol. 2017.

Abstract

Chemotherapeutic agents have limited efficacy and resistance to them limits today and will limit tomorrow our capabilities of cure. Resistance to treatment with anticancer drugs results from a variety of factors including individual variations in patients and somatic cell genetic differences in tumours. In front of this, multimodality has appeared as a promising strategy to overcome resistance. In this context, the use of nanoparticle-based platforms enables many possibilities to address cancer resistance mechanisms. Nanoparticles can act as carriers and substrates for different ligands and biologically active molecules, antennas for imaging, thermal and radiotherapy and, at the same time, they can be effectors by themselves. This enables their use in multimodal therapies to overcome the wall of resistance where conventional medicine crash as ageing of the population advance. In this work, we review the cancer resistance mechanisms and the advantages of inorganic nanomaterials to enable multimodality against them. In addition, we comment on the need of a profound understanding of what happens to the nanoparticle-based platforms in the biological environment for those possibilities to become a reality.

Keywords: Cancer resistance; Inorganic nanoparticles; Multifunctional; Multimodality; Resistance to treatment.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Schematic representation of different cancer treatment modalities that can be integrated in a single NP-based platform
Fig. 2
Fig. 2
Different advantages enabled by a NP platform for a multimodal approach to address cancer resistance

References

    1. Alivisatos AP. Less is more in medicine—sophisticated forms of nanotechnology will find some of their first real-world applications in biomedical research, disease diagnosis and possibly, therapy. Sci Am. 2001;285:66–73. doi: 10.1038/scientificamerican0901-66. - DOI
    1. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, Mignot G, Maiuri MC, Ullrich E, Saulnier P, Yang H, Amigorena S, Ryffel B, Barrat FJ, Saftig P, Levi F, Lidereau R, Nogues C, Mira JP, Chompret A, Joulin V, Clavel-Chapelon F, Bourhis J, Andre F, Delaloge S, Tursz T, Kroemer G, Zitvogel L. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–1059. doi: 10.1038/nm1622. - DOI - PubMed
    1. Auffan M, Rose J, Bottero JY, Lowry GV, Jolivet JP, Wiesner MR. Towards a definition of inorganic nanoparticles from an environmental, health and safety perspective. Nat Nanotechnol. 2009;4(10):634–641. doi: 10.1038/nnano.2009.242. - DOI - PubMed
    1. Auzel FE. Materials and devices using double-pumped phosphors with energy transfer. Proc IEEE. 1973;61(6):758–785. doi: 10.1109/PROC.1973.9155. - DOI
    1. Bachas S, Kohrs B, Wade H. Unconventional coupling between ligand recognition and allosteric control in the multidrug resistance gene regulator, BmrR. ChemMedChem. 2017;12(6):426–430. doi: 10.1002/cmdc.201700017. - DOI - PubMed

LinkOut - more resources